Surface Oncology, Inc.

SURFCIK 0001718108 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed May 1, 2023. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone -0.0008

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Surface Oncology, Inc.

Name	Roles	Filings
Fees Jessica	Officer	5
Oneill Alison	Officer	5
Ross Robert W.	OfficerDirector	5
Palombella Vito J.	Officer	4
Adams Chandra	Officer	3

Showing 1-5 of 17

Per pagePage 1 of 4Next

All filings

42 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Jun 10, 2022	Torres Denice Director	Holdings only	-	-	-
Jun 10, 2022	Shanafelt Armen Director · 10% Owner	Holdings only	-	-	-
Jun 10, 2022	Sigal Charles Elliott Director	Holdings only	-	-	-
Apr 1, 2022	Boni Theresa General Counsel & Secretary	Holdings only	-	-	-
Mar 3, 2022	Palombella Vito J. Chief Scientific Officer	AGrant	38,000	$0.00	$0

Showing 26-30 of 42

Per pagePrevPage 6 of 9Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value